Adaptation: Adjuvant treatment for patients with primary hypercholesterolemia (type Ⅱa, including heterozygous familial hypercholesterolemia) or mixed lipohemia (type Ⅱb) when diet or exercise therapy is not ideal. (Lowering blood lipids)
Pharmacology: Inhibition of HMG-CoA reductase reduces liver cell synthesis and storage of cholesterol, thereby reducing total cholesterol (TC) and low density lipoprotein cholesterol in the blood